FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765450322> ?p ?o ?g. }

• W2765450322 endingPage "A465" @default.
• W2765450322 startingPage "A465" @default.
• W2765450322 abstract "Long-term real-world resource utilization and cost data of mCRC patients eligible for targeted therapies are still scarce. Therefore, more information on treatment cost in current treatment pathways is required to allow informed decision making regarding targeted therapies. Treatment data for patients with mCRC were extracted from the IMS® Oncology Analyzer (OA) database. Based on this, cost for mCRC therapies of currently treated patients were assessed from the perspective of the German Statutory Health Insurance (SHI), using a micro-costing approach. Treatment pathways from 314 patients who had at least two documented lines of therapy were evaluated. 90% of these patients had been tested for RAS status. RAS testing rates for patients with only one documented line of therapy decreased over time from 71% (2014) to 50% (2016). Data show that RAS wildtype (RAS-WT) patients predominantly received Anti-EGFR treatment whereas RAS mutant (RAS-MT) patients mainly received bevacizumab-based therapy. After 1st line therapy, 82% of RAS-WT patients and 20% of RAS-MT patients switched from one targeted therapy to another in 2nd line therapy. For cost analysis data from 1,343 patients with at least one line of treatment was used. Total mean treatment cost for currently treated patients with RAS-WT (€ 19,733) was 10% higher than for RAS-MT patients (€ 18,003). Compared to a similar analysis in 2014, the difference in treatment cost between RAS-WT and RAS-MT patients have decreased by more than 5%. Knowledge of RAS status of mCRC patients affects treatment decisions and allows additional treatment options for RAS-WT patient that are only available for patients who had been tested. Differences in treatment cost for RAS-WT and RAS-MT patients have decreased between 2014 and 2016. The decrease in the RAS testing rate needs to be assessed further to allow best possible treatment for mCRC patients." @default.
• W2765450322 created "2017-11-10" @default.
• W2765450322 creator A5043348604 @default.
• W2765450322 creator A5052749547 @default.
• W2765450322 creator A5060180731 @default.
• W2765450322 creator A5088695982 @default.
• W2765450322 date "2017-10-01" @default.
• W2765450322 modified "2023-10-17" @default.
• W2765450322 title "A Retrospective Database Analysis of Treatment Pathways And Estimated Costs of Treatment In Metastatic Colorectal Carcinoma (MCRC) In Germany" @default.
• W2765450322 doi "https://doi.org/10.1016/j.jval.2017.08.380" @default.
• W2765450322 hasPublicationYear "2017" @default.
• W2765450322 type Work @default.
• W2765450322 sameAs 2765450322 @default.
• W2765450322 citedByCount "0" @default.
• W2765450322 crossrefType "journal-article" @default.
• W2765450322 hasAuthorship W2765450322A5043348604 @default.
• W2765450322 hasAuthorship W2765450322A5052749547 @default.
• W2765450322 hasAuthorship W2765450322A5060180731 @default.
• W2765450322 hasAuthorship W2765450322A5088695982 @default.
• W2765450322 hasBestOaLocation W27654503221 @default.
• W2765450322 hasConcept C121608353 @default.
• W2765450322 hasConcept C126322002 @default.
• W2765450322 hasConcept C143998085 @default.
• W2765450322 hasConcept C2776694085 @default.
• W2765450322 hasConcept C2777802072 @default.
• W2765450322 hasConcept C2781230642 @default.
• W2765450322 hasConcept C526805850 @default.
• W2765450322 hasConcept C71924100 @default.
• W2765450322 hasConceptScore W2765450322C121608353 @default.
• W2765450322 hasConceptScore W2765450322C126322002 @default.
• W2765450322 hasConceptScore W2765450322C143998085 @default.
• W2765450322 hasConceptScore W2765450322C2776694085 @default.
• W2765450322 hasConceptScore W2765450322C2777802072 @default.
• W2765450322 hasConceptScore W2765450322C2781230642 @default.
• W2765450322 hasConceptScore W2765450322C526805850 @default.
• W2765450322 hasConceptScore W2765450322C71924100 @default.
• W2765450322 hasIssue "9" @default.
• W2765450322 hasLocation W27654503221 @default.
• W2765450322 hasOpenAccess W2765450322 @default.
• W2765450322 hasPrimaryLocation W27654503221 @default.
• W2765450322 hasRelatedWork W1907211896 @default.
• W2765450322 hasRelatedWork W2066973685 @default.
• W2765450322 hasRelatedWork W2069007718 @default.
• W2765450322 hasRelatedWork W2402935083 @default.
• W2765450322 hasRelatedWork W2464790776 @default.
• W2765450322 hasRelatedWork W2588306759 @default.
• W2765450322 hasRelatedWork W2784706285 @default.
• W2765450322 hasRelatedWork W3030758306 @default.
• W2765450322 hasRelatedWork W3152235123 @default.
• W2765450322 hasRelatedWork W76115934 @default.
• W2765450322 hasVolume "20" @default.
• W2765450322 isParatext "false" @default.
• W2765450322 isRetracted "false" @default.
• W2765450322 magId "2765450322" @default.
• W2765450322 workType "article" @default.